IDF Releases New Position Statement on 1-hour OGTT for Diagnosis of Prediabetes and T2DM - Ft. Dr V Mohan
The International Diabetes Federation (IDF) released a Position Statement recommending use of 1-hour post-load plasma glucose (1-h PG) test as a more sensitive and practical method to screen for intermediate hyperglycaemia (IH), (earlier known as Pre-Diabetes) and type 2 diabetes(T2D) in people at risk.The Statement was prepared by an international panel of 22 experts from 15 countries...
The International Diabetes Federation (IDF) released a Position Statement recommending use of 1-hour post-load plasma glucose (1-h PG) test as a more sensitive and practical method to screen for intermediate hyperglycaemia (IH), (earlier known as Pre-Diabetes) and type 2 diabetes(T2D) in people at risk.
The Statement was prepared by an international panel of 22 experts from 15 countries and presented recently at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Florence, Italy and was published online in Diabetes Research and Clinical Practice. Dr. V. Mohan, Chairman, Madras Diabetes Research Foundation and Dr. Mohan;s Diabetes Specialities Centre represented India on this panel.
The Statement recommends the use of 1-h PG with the validated cut points of 155 mg/dL (8.6 mmol/L) for IH and 209 mg/dL(11.6 mmol/L) for T2D. Intermediate Hyperglycaemia is a state between normal glucose regulation (NGR) and T2D. It includes impaired fasting glycaemia (IFG) and impaired glucose tolerance (IGT).
Many individuals with intermediate Hyperglycaemia as defined by current diagnostic criteria, will progress to T2D. Evidence shows that T2D can be prevented by lifestyle modification and/or medications in people with IGT diagnosed by 2-h PG during a 75-gram oral glucose tolerance test (OGTT). Unfortunately, many people with T2D and those with IGT remain undiagnosed if an OGTT is not employed. Given the continued rising prevalence of diabetes worldwide, a more sensitive and practical method is therefore needed to detect people with IH and T2D for early diagnosis and intervention.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd